Treatment with EGCG was shown to decrease VEGF expression in ESCC cell lines (Te-1 and Eca-109) and suppress angiogenesis in the patient-derived tumor xenograft (PDX) model of EC. This evidence concerns the gene VEGFA and esophageal squamous cell carcinoma.